L. Hargarter

611 total citations
33 papers, 497 citations indexed

About

L. Hargarter is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Clinical Psychology. According to data from OpenAlex, L. Hargarter has authored 33 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 8 papers in Pediatrics, Perinatology and Child Health and 7 papers in Clinical Psychology. Recurrent topics in L. Hargarter's work include Schizophrenia research and treatment (24 papers), Attention Deficit Hyperactivity Disorder (8 papers) and Pharmaceutical studies and practices (7 papers). L. Hargarter is often cited by papers focused on Schizophrenia research and treatment (24 papers), Attention Deficit Hyperactivity Disorder (8 papers) and Pharmaceutical studies and practices (7 papers). L. Hargarter collaborates with scholars based in Germany, France and Netherlands. L. Hargarter's co-authors include A. Schreiner, Paul Bergmans, Sofia Keim, Philip Gorwood, Georg Juckel, Martin Brüne, Henning Witthaus, Ute Naumann, Idun Uhl and Hans‐Werner Bierhoff and has published in prestigious journals such as Psychopharmacology, Schizophrenia Research and Pediatric Research.

In The Last Decade

L. Hargarter

33 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Hargarter Germany 12 453 151 147 52 46 33 497
B. Lachaux France 9 476 1.1× 182 1.2× 227 1.5× 58 1.1× 40 0.9× 30 601
W. Gaebel Germany 10 431 1.0× 178 1.2× 164 1.1× 52 1.0× 43 0.9× 33 542
Corina Young United Kingdom 9 530 1.2× 102 0.7× 154 1.0× 84 1.6× 30 0.7× 11 630
Patricia L. Gilbert United States 3 305 0.7× 101 0.7× 95 0.6× 43 0.8× 41 0.9× 5 352
Petrus Oosthuizen South Africa 7 339 0.7× 136 0.9× 137 0.9× 27 0.5× 38 0.8× 8 377
N. Keyter South Africa 10 314 0.7× 149 1.0× 104 0.7× 48 0.9× 36 0.8× 12 451
Ralph Aquila United States 10 357 0.8× 111 0.7× 77 0.5× 77 1.5× 26 0.6× 15 446
W. Chrzanowski Poland 7 413 0.9× 96 0.6× 110 0.7× 126 2.4× 60 1.3× 11 497
Sandra Zirul Canada 7 314 0.7× 97 0.6× 88 0.6× 40 0.8× 36 0.8× 8 396
Eun Kee Chung South Korea 11 347 0.8× 107 0.7× 88 0.6× 80 1.5× 21 0.5× 15 454

Countries citing papers authored by L. Hargarter

Since Specialization
Citations

This map shows the geographic impact of L. Hargarter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Hargarter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Hargarter more than expected).

Fields of papers citing papers by L. Hargarter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Hargarter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Hargarter. The network helps show where L. Hargarter may publish in the future.

Co-authorship network of co-authors of L. Hargarter

This figure shows the co-authorship network connecting the top 25 collaborators of L. Hargarter. A scholar is included among the top collaborators of L. Hargarter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Hargarter. L. Hargarter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mathews, Maju, Srihari Gopal, Isaac Nuamah, et al.. (2019). <p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>. Neuropsychiatric Disease and Treatment. Volume 15. 1365–1379. 31 indexed citations
2.
Savitz, Adam, Haiyan Xu, Srihari Gopal, et al.. (2019). <p>Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population</p>. Neuropsychiatric Disease and Treatment. Volume 15. 587–602. 4 indexed citations
3.
Emsley, Robin, et al.. (2017). Once-monthly paliperidone palmitate in early stage schizophrenia &ndash; a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatric Disease and Treatment. Volume 13. 2261–2269. 9 indexed citations
4.
Hargarter, L., et al.. (2016). Channeling Bias In Comparative-Effectiveness Research Of Newly Launched Medications: A Case Study. Value in Health. 19(3). A184–A184. 2 indexed citations
5.
6.
Schreiner, A., Kaire Aadamsoo, A.C. Altamura, et al.. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Research. 169(1-3). 393–399. 115 indexed citations
7.
Schreiner, A., Paul Bergmans, Sofia Keim, et al.. (2014). A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. Clinical Therapeutics. 36(10). 1372–1388.e1. 31 indexed citations
8.
Schreiner, A., et al.. (2014). Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). Current Medical Research and Opinion. 30(7). 1279–1289. 8 indexed citations
9.
Hargarter, L., Paul Bergmans, Sofia Keim, et al.. (2014). Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 58. 1–7. 48 indexed citations
10.
11.
Gorwood, Philip, Tom Burns, Georg Juckel, et al.. (2013). Psychiatrists’ perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. Annals of General Psychiatry. 12(1). 8–8. 11 indexed citations
12.
13.
Ibach, Bernd, Jonathan Rabinowitz, A. Schreiner, L. Hargarter, & Bettina Diekamp. (2010). LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY. Schizophrenia Research. 117(2-3). 527–527. 1 indexed citations
14.
Juckel, Georg, Ute Naumann, Idun Uhl, et al.. (2008). Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophrenia Research. 104(1-3). 287–293. 89 indexed citations
15.
Fegert, Jörg M., et al.. (2007). Treatment with methylphenidate in childhood and adolescence. Conclusions reached at an expert consensus conference. Monatsschrift Kinderheilkunde. 155(8). 1 indexed citations
16.
Karlsson, Per, L. Hargarter, Sigrid Nyberg, et al.. (2007). Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115). Pharmacopsychiatry. 40(5). 17 indexed citations
17.
Vermeir, Marc, et al.. (2007). Absorption; metabolism and excretion of a single oral dose of 14c-paliperidone 1mg in healthy subjects (PAL-053). Pharmacopsychiatry. 40(5). 15 indexed citations
18.
Fegert, Jörg M., et al.. (2007). Behandlung mit Methylphenidat im Kindesalter. Monatsschrift Kinderheilkunde. 155(8). 747–752. 1 indexed citations
19.
Gjedde, Albert, et al.. (1997). Regional Cerebral Glucose Utilization in Immature Fetal Guinea Pigs during Maternal Isocapnic Hypoxemia. Pediatric Research. 42(3). 311–316. 5 indexed citations
20.
Gallhofer, B., Stefan H. Krieger, Stefanie Lis, et al.. (1997). Cognitive Dysfunction in Schizophrenia: Maze-Solving Behavior in Treated and Untreated Patients. CNS Spectrums. 2(8). 26–40. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Lachaux Breakdown of academic impact, for papers by W. Gaebel Breakdown of academic impact, for papers by Corina Young Breakdown of academic impact, for papers by Patricia L. Gilbert Breakdown of academic impact, for papers by Petrus Oosthuizen Breakdown of academic impact, for papers by N. Keyter Breakdown of academic impact, for papers by Ralph Aquila Breakdown of academic impact, for papers by W. Chrzanowski Breakdown of academic impact, for papers by Sandra Zirul Breakdown of academic impact, for papers by Eun Kee Chung
Rankless by CCL
2026